Welcome to InfiCure Bio
InfiCure Bio is a life science company focusing on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions.
Based on a panel of in vivo models for these conditions including a proprietary model, the NIF mouse, for chronic inflammation and fibrosis, we offer effect tests of anti-inflammatory and anti-fibrotic drugs.
Founded on extensive experience and expertise in immunology, inflammation and fibrosis research, InfiCure Bio offers a proficient and flexible processing of drug validation projects in this area.
News
Sofia Mayans participates in national pitching event 29th of January 2021
Sofia Mayans, CEO at InfiCure Bio, will participate in the national pitching competition "Hela Sverige Pitchar" by Connect Sverige. InfiCure Bio is one of 5 companies in Life Science/MedTech that will pitch on January 29 [...]
Pressrelease: InfiCure Bio secures US patent and publishes new data in a top scientific journal
https://www.mynewsdesk.com/se/umeaa-biotech-incubator/pressreleases/inficure-bio-secures-us-patent-and-publishes-new-data-in-a-top-scientific-journal-3060618?utm_source=rss&utm_medium=rss&utm_campaign=Alert&utm_content=pressrelease
New publication on the liver phenotype of the NIF mouse
Check out our new exciting study describing the liver phenotype of the NIF mouse! We are proud to announce that it has been accepted for publication in Scientific Reports (https://lnkd.in/emhf8h7). In this paper we demonstrate [...]
InfiCure Bio will attend the annual NASH Summit in mid December
InfiCure Bio AB will attend the 4th NASH Summit (https://nash-summit.com) in mid December and our CEO Sofia Mayans will give a talk on our unique NIF mouse on December 16th at 2.45pm EST. Do not [...]